Skip to main content

Table 1 Baseline patient characteristics

From: Beta-hydroxy beta-methylbutyrate/arginine/glutamine (HMB/Arg/Gln) supplementation to improve the management of cachexia in patients with advanced lung cancer: an open-label, multicentre, randomised, controlled phase II trial (NOURISH)

  HMB/Arg/Gln
n = 19
N (%)
No HMB/Arg/Gln
n = 19
N (%)
All
n = 38
N (%)
Age 60 or below 6 (32) 6 (32) 12 (32)
Over 60 13 (68) 13 (68) 26 (68)
Sex Male 12 (63) 11 (58) 23 (61)
Female 7 (37) 8 (42) 15 (39)
Diagnosis SCLC 3 (16) 3 (16) 6 (16)
NSCLC 16 (84) 16 (84) 32 (84)
Staginga Locally advanced 8 (42) 6 (32) 14 (37)
Metastatic 11 (58) 13 (68) 24 (63)
WHO Performance status 0 2 (10.5) 7 (37) 9 (24)
1 15 (79) 11 (58) 26 (68)
2 2 (10.5) 1 (5) 3 (8)
  1. aCorrelative staging has been added retrospectively for information, but was not collected at the time of the trial: Locally advanced = Stage 3B NSCLC; Metastatic = Stage 4 NSCLC and extensive stage SCLC
  2. SCLC small-cell lung cancer, NSCLC non-small-cell lung cancer, HMB/Arg/Gln β-Hydroxy β-Methylbutyrate/Arginine/Glutamine